Focused On-demand Library for Ubiquitin carboxyl-terminal hydrolase MINDY-1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q8N5J2

UPID:

MINY1_HUMAN

Alternative names:

Deubiquitinating enzyme MINDY-1; Protein FAM63A

Alternative UPACC:

Q8N5J2; B3KWP4; B3KWV8; B4DXF2; B4E1S4; D3DV09; J3KP53; Q5SZF0; Q9NUL9; Q9P2F7

Background:

Ubiquitin carboxyl-terminal hydrolase MINDY-1, also known as Deubiquitinating enzyme MINDY-1 or Protein FAM63A, plays a crucial role in protein turnover. It is a hydrolase that specifically targets 'Lys-48'-linked conjugated ubiquitin, preferring long polyubiquitin chains for removal from proteins. This activity suggests a regulatory function in the degradation and recycling of proteins.

Therapeutic significance:

Understanding the role of Ubiquitin carboxyl-terminal hydrolase MINDY-1 could open doors to potential therapeutic strategies. Its unique ability to process long polyubiquitin chains positions it as a key player in maintaining cellular protein homeostasis, a process often disrupted in diseases.